Results 201 to 210 of about 26,552 (294)
Chemistry &Biodiversity, Volume 23, Issue 9, September 2026.A series of substituted indolo[2,1‐b]quinazoline‐6,12‐diones (SJ1‐SJ8) has been studied for their possible α‐amylase inhibition property as an antidiabetic lead compound. The most potent inhibitory activity among the tested derivatives was showed by SJ2 (IC50 = 18.49 ± 0.06 µM), similar to the reference drug acarbose (IC50 = 16.26 ± 0.02 µM).
Sahil Jaidka +4 more
wiley +1 more source
Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses. [PDF]
Front Endocrinol (Lausanne)Jun JE +7 more
europepmc +1 more source
Type 5 Diabetes Mellitus: Pathophysiology, Clinical Phenotype, and Nutritional Management
Diabetes/Metabolism Research and Reviews, Volume 42, Issue 6, September 2026.ABSTRACT Type 5 Diabetes Mellitus (T5DM) is an emerging diabetes phenotype linked to chronic undernutrition. It predominantly affects young, lean individuals in low‐ and middle‐income countries. After its formal recognition by the International Diabetes Federation in 2025, T5DM resurfaced as a clinically relevant insulin‐deficient phenotype.
İrem Nur Şahin Anılgan +1 more
wiley +1 more source
Insulin autoimmune hypoglycemia unmasking monoclonal gammopathy in type 2 diabetes. [PDF]
JCEM Case RepPrasad S +5 more
europepmc +1 more source
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.This prospective observational study evaluated changes in dietary patterns and body composition after 3 months of oral semaglutide treatment in people with Type 2 diabetes. Oral semaglutide was associated with reduced energy intake, salt intake and body fat while preserving handgrip strength.
Mika Sawada +9 more
wiley +1 more source
Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation. [PDF]
BMJ MedXie Y, Choi T, Al-Aly Z.
europepmc +1 more source
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.DPP‐4 Inhibitors associated withheart failure events in patients with type‐2 diabetes. This study found statistically insignificant summary effect for all DPP‐4 inhibitors combined but found asignificant association of saxagliptin with heart failure events (RR = 1.24, 95% CI 1.05–1.47). Results are to be interpreted with caution.
Shishir Nepal, Shiva Prasad Nepal
wiley +1 more source
Bisoprolol and Amlodipine Co-Administration with Glimepiride in a Diabetic Rat Model: A Statistical and Machine Learning Analysis. [PDF]
Pharmaceuticals (Basel)Hailat M +6 more
europepmc +1 more source
Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.The comparative pharmacology and cardiometabolic outcomes of semaglutide, liraglutide and tirzepatide, integrating evidence from major clinical trial programs and meta‐analyses. ABSTRACT Background Cardiometabolic disorders such as type 2 diabetes mellitus (T2DM), obesity and cardiovascular disease (CVD) remain major global health challenges.
Hiba Bawadi +4 more
wiley +1 more source